Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyFRA:3NK +0.57%55 Days Inventory is 535.76 as of Dec. 2025, which is 1% above its 10-year median of 528.97. GuruFocus rates FRA:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.82. The stock has 4 warning signs investors should review. Among 639 Biotechnology companies, Alphamab Oncology ranks worse than 82.47% on this metric.
The historical rank and industry rank for Alphamab Oncology's Days Inventory or its related term are showing as below:
FRA:3NK'
s Days Inventory Range Over the Past 10 Years
Min: 478.21 Med: 528.97 Max: 6075.75
Current: 516.11
During the past 9 years, Alphamab Oncology's highest Days Inventory was 6075.75. The lowest was 478.21. And the median was 528.97.
FRA:3NK's Days Inventory is ranked worse than 82.47% of 639
companies
in the Biotechnology industry
Industry Median: 182.51
vs FRA:3NK: 516.11
Alphamab Oncology's Days Inventory
increased
from Dec. 2024 (449.65) to Dec. 2025 (535.76).
It might indicate that Alphamab Oncology's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Alphamab Oncology's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alphamab Oncology's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.38.
Alphamab Oncology (FRA:3NK) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Alphamab Oncology's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alphamab Oncology's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Alphamab Oncology Days Inventory Related Terms
Alphamab Oncology Days Inventory Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3NK vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Alphamab Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (FRA:3NK) has a Days Inventory of 535.76 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alphamab Oncology and its competitors. This is near median its historical median of 528.97. Over the past decade, Alphamab Oncology's Days Inventory has ranged from 478.21 to 6,075.75. According to the industry distribution chart, Alphamab Oncology ranks #527 out of 639 companies in the Biotechnology industry, placing it in the top 82.5%.
Is Alphamab Oncology's Days Inventory too high?
Alphamab Oncology's current Days Inventory of 535.76 is near median its 10-year median of 528.97. Over the past 10 years, this metric has ranged from a low of 478.21 to a high of 6,075.75. The Biotechnology industry median Days Inventory is 182.51. Alphamab Oncology's value of 535.76 is 193.6% above this industry median. Based on the distribution chart, Alphamab Oncology ranks #527 out of 639 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #527 out of 639 companies for Days Inventory. This places Alphamab Oncology in the lower half of its industry. The industry median Days Inventory is 182.51. Alphamab Oncology's value of 535.76 is 193.6% above this benchmark. Historically, Alphamab Oncology's own Days Inventory has ranged from 478.21 to 6,075.75 over the past decade. While the company's 10-year median is 528.97 vs. the industry median of 182.51, Alphamab Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.51, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alphamab Oncology's current Days Inventory of 535.76 is 193.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median Days Inventory is 182.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current Days Inventory is 535.76, which is near median its own 10-year median of 528.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current Days Inventory of 535.76. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current Days Inventory is 535.76, which is near median its 10-year median of 528.97 and 193.6% above the Biotechnology industry median of 182.51. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current Days Inventory is 535.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.
Key valuation signals for FRA:3NK:
Days Inventory: 535.76 (near median its 10-year median of 528.97)
GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
Industry Position: 193.6% above the Biotechnology median (#527 of 639)
No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for FRA:3NK
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3NK has been successfully added to your 
